FOXP3 and neoplasm: Although studies using the PROTACs in targeting Tregs are very limited, we believe that this innovative approach holds great promise in drug development, offering a precise means of modulating cellular processes by selectively eliminating Foxp3, with potential in anti-tumor immunity.